日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography.

采用 (18)F-3'脱氧-3'氟-L-胸苷正电子发射断层扫描/计算机断层扫描评估阿昔替尼在晚期恶性肿瘤患者中的药效学研究

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-015-2779-7
Bruce Justine Yang, Scully Peter Colin, Carmichael Lakeesha L, Eickhoff Jens C, Perlman Scott B, Kolesar Jill Marie, Heideman Jennifer L, Jeraj Robert, Liu Glenn
肿瘤
肿瘤免疫
发表日期：2015
文献求助 收藏

A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies

一项针对肾细胞癌和其他晚期实体恶性肿瘤患者的舒尼替尼联合贝伐单抗序贯治疗的I期药效学试验

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-013-2373-9
Bruce, Justine Yang; Kolesar, Jill M; Hammers, Hans; Stein, Mark N; Carmichael, Lakeesha; Eickhoff, Jens; Johnston, Susan A; Binger, Kimberly A; Heideman, Jennifer L; Perlman, Scott B; Jeraj, Robert; Liu, Glenn
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2014
文献求助 收藏